06 Feb 24
London, U.K. 6th February 2024: tranScrip, the leading contract drug development organisation, announces that Gareth Dyson has been named Chief Financial Officer (“CFO”) with immediate effect. Gareth has a wealth of finance and leadership experience in Private Equity backed businesses and has a track record of driving significant growth and transformation in fast paced B2B environments. His experience spans financial management, mergers and acquisitions, systems implementation, and leading large teams.
Prior to joining tranScrip, Gareth was Chief Financial Officer at Redstor, a data management and protection vendor, where he completed one acquisitions and two successful private equity transactions.
Gareth’s expertise and experience will help tranScrip continue to develop and grow as a trusted partner for the pharmaceutical and biotech industry and help make a real difference to the lives of patients.
Mark Corbett, tranScrip’s CEO, said:
Gareth Dyson, tranScrip’s CFO, said:
We have teams of life science and R&D experts to help achieve your goals and seize opportunities. Whatever your project requires, we have the people to meet your needs.